An observational study in Prostatic Neoplasms, Castration-Resistant, sponsored by Bayer. Completed at 1 site in Belgium. Open to male participants. Per ClinicalTrials.gov, last updated 2020-05-20.
Sponsored by Bayer · Observational
The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated with this proportion.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,397 are open to participants now.
This study's enrollment of 164 is below the median of 200 across 1,179 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Bayer is the lead sponsor of 1,643 studies on the registry; 57 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 129 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Belgian patients who were treated with Radium-223 for (metastatic) Castration Resistant Prostate Cancer
Exclusion Criteria:
Belgium patients with a diagnosis of mCRPC (no known visceral metastases) and who were treated with Radium-223 for this indication
Drug: Radium-223 (Xofigo, Bay88-8223)
Follow the physician's prescription in routine clinical practice.
The proportion of patients with 5-6 Radium-223 injections versus 1-4 Radium-223 injections
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The proportion of patients with 5-6 Radium-223 injections versus 1-4 Radium-223 injections by Radium-223 line of treatment (1st, 2nd and further line)
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The number of prior and post life prolonging systemic anti-cancer therapies will be described
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The characteristics of patients according to the experience of the study centers with Radium-223
By stratification according to the number of months after the very first index date per center
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The occurrence of progression post first dose of Radium-223
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The occurrence of SSE related hospitalizations
SSE: Symptomatic Skeletal Events
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The frequency of SSE related hospitalizations
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The number of discontinuation of Radium-223
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The frequency of blood transfusions
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The overall survival in routine clinical practice
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The number of patients receiving first- and second-line systemic anti-cancer treatment in mCRPC
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The timing of progression post first dose of Radium-223
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The time between last Radium-223 injection and next line of systemic anti-cancer therapy
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
The number of patients receiving next line of systemic anti-cancer therapy
Time frame: Retrospectively analysis from 22 December 2013 to 01 June 2018
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer